Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.

Authors: Song, S  Crow, AR  Siragam, V  Freedman, J  Lazarus, AH 
Citation: Song S, etal., Blood. 2005 Feb 15;105(4):1546-8. Epub 2004 Oct 12.
Pubmed: (View Article at PubMed) PMID:15479722
DOI: Full-text: DOI:10.1182/blood-2004-05-1886

The mechanism of action of intravenous immunoglobulin (IVIg) and polyclonal anti-D-mediated reversal of immune thrombocytopenia (ITP) is still unclear. However, in a murine model of ITP, the therapeutic effect of IVIg appears to be wholly dependent upon the expression of the inhibitory Fc receptor, Fc gamma RIIB. We previously demonstrated that, similar to anti-D in humans, 2 erythrocyte-reactive monoclonal antibodies (TER119 and M1/69) ameliorated murine ITP and inhibited reticuloendothelial system (RES) function at doses that protected against thrombocytopenia. The current study evaluated the involvement of the inhibitory and activating Fc receptors, Fc gamma RIIB and Fc gamma RIIIA, respectively, in the TER119 and M1/69-mediated inhibition of thrombocytopenia. In contrast to IVIg, in Fc gamma RIIB-deficient mice, both monoclonal antibodies ameliorated ITP and both significantly down-regulated the level of expression of the activating Fc gamma RIIIA in splenic macrophages. These results indicate that anti-erythrocyte antibodies that ameliorate ITP act independently of Fc gamma RIIB expression but are dependent upon the activating Fc gamma RIIIA.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11344926
Created: 2016-07-08
Species: All species
Last Modified: 2016-07-08
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.